# Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT00124280** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 85 (actual)

## Conditions studied

- Non-small-cell Lung Carcinoma

## Interventions

- **DRUG:** RAD001

## Key facts

- **NCT ID:** NCT00124280
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-10
- **Final completion:** —
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124280, "Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00124280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*